Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement activation by beta-amyloid in Alzheimer disease.

J Rogers1, N R Cooper, S Webster

  • 1L. J. Roberts Center, Sun Health Research Institute, Sun City, AZ 85351.

Proceedings of the National Academy of Sciences of the United States of America
|November 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement activation by neurofibrillary tangles in Alzheimer's disease.

Neuroscience letters·2001
Same author

Inflammation and Alzheimer's disease.

Neurobiology of aging·2000
Same author

Pelvic bioelectrical impedance measurements to detect rectal filling.

Physiological measurement·1998
Same author

Teratoma with trisomy 16 in a baboon (Papio hamadryas).

American journal of primatology·1998
Same author

Comparison of pleural fluid pH values obtained using blood gas machine, pH meter, and pH indicator strip.

Chest·1998
Same author

Obesity in older persons.

Journal of the American Dietetic Association·1998

Alzheimer disease involves beta-amyloid peptide (beta-AP) buildup. This study shows beta-AP directly activates the complement system, a key immune pathway, potentially explaining its neurotoxicity in Alzheimer brains.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Alzheimer disease (AD) is marked by beta-amyloid peptide (beta-AP) accumulation in the brain.
  • The precise mechanism of beta-AP neurotoxicity in AD remains incompletely understood.
  • The complement system is a crucial part of the innate immune response.

Purpose of the Study:

  • To investigate whether beta-amyloid peptide can directly activate the complement system.
  • To explore the role of complement activation in Alzheimer disease pathology.

Main Methods:

  • In vitro experiments to assess beta-AP binding and complement activation.
  • In situ analysis of complement activation markers in Alzheimer disease brain tissue.

Main Results:

Related Experiment Videos

  • Direct evidence shows beta-AP binds and activates the classical complement pathway without antibodies.
  • In situ findings link complement activation to AD pathology in affected brain regions.

Conclusions:

  • Beta-amyloid peptide can directly trigger the complement cascade.
  • Complement activation by beta-AP represents a potential mechanism for neurotoxicity in Alzheimer disease.